Biocytogen Pharmaceuticals Beijing (2315) H1 2024 earnings summary

Executive summary

• H1 revenue rose 25.6% YoY to RMB410.5m; net loss narrowed 73.3% to RMB50.7m, and operating cash flow turned positive at RMB29.6m.

• Growth was led by animal-model sales and antibody development; overseas revenue reached RMB293.5m, or 71.5% of total revenue.

• Management targeted H2 profitability and FY 2024 breakeven or near-breakeven, with cost controls and continued core R&D investment.

Financial highlights

• Revenue was RMB410.5m versus RMB326.8m YoY; gross profit rose 29.8% to RMB305.5m and gross margin expanded to 74.4% from 72.0%.

• Reported operating profit was RMB14.7m versus an operating loss of RMB137.7m; loss before tax was RMB47.1m versus RMB189.4m.

• Net loss was RMB50.7m versus RMB189.8m; basic and diluted loss per share improved to RMB0.13 from RMB0.48.

• R&D expense fell 34.8% to RMB161.7m and G&A fell 12.7% to RMB102.6m; selling and marketing expense rose 44.1% to RMB42.5m.

• Finance costs rose 12.8% YoY to RMB52.7m, mainly due to higher interest on bank and other loans.

Outlook and guidance

• Management targeted H2 2024 profitability and FY 2024 results at or near breakeven, supported by revenue growth, cost control and operating-efficiency measures.

• Plans include continued R&D investment in core platforms and animal models, and expanding ready-to-license libraries in bispecifics, ADCs, nanobodies, TCR-like and GPCR antibodies.

• Strategy is to advance selected assets to preclinical or early clinical stages for licensing or co-development; no near-term plans to lead late-stage development or commercialization internally.

• Future antibody monetization is expected to include upfront and milestone payments and royalties; current annual sales revenue mainly comprises upfront and some milestone fees.

• Further overseas team investment and localized Boston services aim to deepen international client relationships and support overseas growth.